Hematologic Malignancies Program

$153,745P30FY2012CANIH

University Of Pennsylvania, Philadelphia PA

Investigators

Linked publications & trials

Paper 39650645 Paper 39642942 Paper 39461879 Paper 39298269 Paper 39287991 Paper 39262197 Paper 39253495 Paper 39214097 Paper 39198645 Paper 39121847 Paper 39108509 Paper 39108244 Paper 39108237 Paper 39075237 Paper 39052709 Paper 39047033 Paper 39041214 Paper 39041040 Paper 39026781 Paper 39018057 Paper 39007142 Paper 38993651 Paper 38982051 Paper 38950325 Paper 38909912 Paper 38900977 Paper 38891035 Paper 38886328 Paper 38885087 Paper 38826355 Paper 38826316 Paper 38753757 Paper 38739715 Paper 38724204 Paper 38701911 Paper 38695869 Paper 38680111 Paper 38652549 Paper 38577979 Paper 38529551 Paper 38520894 Paper 38496424 Paper 38473352 Paper 38419362 Paper 38394613 Paper 38363547 Paper 38362346 Paper 38352551 Paper 38263597 Paper 38253811 Paper 38197423 Paper 38191994 Paper 38185471 Paper 38100526 Paper 38095447 Paper 38094200 Paper 38091951 Paper 38049632 Paper 38047502 Paper 38036590 Paper 38014202 Paper 37958304 Paper 37926618 Paper 37910501 Paper 37848036 Paper 37832945 Paper 37806616 Paper 37790930 Paper 37745398 Paper 37735588 Paper 37723305 Paper 37649085 Paper 37607999 Paper 37603482 Paper 37593202 Paper 37592014 Paper 37591698 Paper 37574596 Paper 37572187 Paper 37571390 Paper 37548980 Paper 37527035 Paper 37515169 Paper 37505079 Paper 37492275 Paper 37491927 Paper 37489471 Paper 37467321 Paper 37460741 Paper 37376417 Paper 37371629 Paper 37368544 Paper 37365276 Paper 37246069 Paper 37224816 Paper 37222130 Paper 37217520 Paper 37166575 Paper 37133746 Paper 37130837

Abstract

The Hematologic Malignancies Program has two overarching scientific goals. These are to: 1. Employ state of the art technology to develop mechanisms based understanding of the cellular, biochemical, and molecular biology of normal and malignant hemato-lymphopoiesis. 2. Translate basic scientific discoveries into rational therapies that are more tumoricidal but at the same time, less toxic to normal tissues. To accomplish these goals, the investigators organize within thematic areas in both basic and clinical science. All areas focus on translation as a goal of the wori< conducted. Basic scientists focus on transcription, signal transduction, and animal modeling of disease pathogenesis and treatment. Clinical scientists self-align with one of 4 affinity groups: Leukemia/MDS/MPN, Lymphoma, Myeloma/Autologous Stem Cell Transplantation, or Allogeneic Stem Cell Transplantation. Individual investigators, basic or clinical, function autonomously, but the structure of this ACC program promotes collaboration with shared data, ideas, and when appropriate to implement initial translational studies. Promising approaches are brought quickly to clinical trials (see Figure 1).

View original record on NIH RePORTER →